JP2705787B2 - Easy to take bitterness improving H 改善 2H blocker solid preparation - Google Patents

Easy to take bitterness improving H 改善 2H blocker solid preparation

Info

Publication number
JP2705787B2
JP2705787B2 JP6237963A JP23796394A JP2705787B2 JP 2705787 B2 JP2705787 B2 JP 2705787B2 JP 6237963 A JP6237963 A JP 6237963A JP 23796394 A JP23796394 A JP 23796394A JP 2705787 B2 JP2705787 B2 JP 2705787B2
Authority
JP
Japan
Prior art keywords
solid preparation
blocker
less
bitterness
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP6237963A
Other languages
Japanese (ja)
Other versions
JPH0899904A (en
Inventor
佳己 橋本
浩美 塩沢
英之 岸本
政弘 池田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Priority to JP6237963A priority Critical patent/JP2705787B2/en
Publication of JPH0899904A publication Critical patent/JPH0899904A/en
Application granted granted Critical
Publication of JP2705787B2 publication Critical patent/JP2705787B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は,溶解熱が−60KJ/
kg以下好ましくは−100KJ/kg以下の糖アルコ
ールを添加してなる,苦味改善易服用性H2ブロッカー
固形製剤及びその製造法に関するものである。
BACKGROUND OF THE INVENTION The present invention relates to a method for producing a material having a heat of dissolution of -60 KJ /
The present invention relates to an easy-to-take bitterness-improving solid dosage form of H 2 blocker, which is obtained by adding a sugar alcohol of not more than kg, preferably not more than -100 KJ / kg, and a method for producing the same.

【0002】[0002]

【従来の技術】従来、医薬品を用いた治療においては,
その効果に重点がおかれた方法がとられていた。現在は
高度に経済が発達し,様々な物質があふれ,豊かな暮ら
しができるようになり,老齢人口の増加や,ストレス等
が問題となってくるにつれ,快適さ,好適さが要求さ
れ,人々の生活の質(Quality of life)の向上が唱え
られてきている。治療においても同じ医薬品を投与する
ならば,患者にとってより好ましい,苦味,苦痛等を伴
わない製剤,服用時に多量の水を摂取することを要しな
い,利用しやすい製剤の開発が望まれている。正確な服
薬は薬物療法を行なう前提であり,患者が服薬を守らな
い限り,薬物治療効果をあげることはできない。しか
し,患者が服薬を正確にしていない比率は驚く程高く,
患者が服薬を守っていると答えたにもかかわらず,薬物
血中濃度を測定した結果,服薬していないことが判明し
た事例もある。
2. Description of the Related Art Conventionally, in the treatment using pharmaceuticals,
A method was used that emphasized its effects. At present, the economy is highly developed, various substances are overflowing, and we can live a rich life. As the elderly population increases and stress becomes a problem, comfort and suitability are required. Improvement of the quality of life has been advocated. If the same drug is administered in the treatment, there is a demand for the development of a formulation that is more favorable for patients, does not involve bitterness, pain, etc., and does not require a large amount of water when taken, and is easy to use. Precise medication is a prerequisite for drug therapy, and unless the patient adheres to the medication, the drug therapy cannot be effective. However, the rate at which patients do not take medication accurately is surprisingly high,
In some cases, patients have responded that they are taking medication, but have determined that they have not taken medication by measuring drug blood levels.

【0003】よって患者のコンプライアンス(服薬遵
守),つまり投薬後患者がどの程度真面目に指示どおり
服用しているかが重要となってくる。口に合わない製剤
は患者が服用を怠る原因にもなり得,その改善はコンプ
ライアンスの向上につながる。ファモチジン,シメチジ
ン,塩酸ラニチジン,ニザチジン,塩酸ロキサチジンア
セタート等のH2ブロッカーは,カプセル剤,錠剤及び
散剤として処方されている。水に極めて溶けにくいもの
の,散剤,顆粒剤及び咀嚼可能な錠剤など表面積が広
く,口腔内に暫時滞留する剤型においては苦味のため服
用時に抵抗感が生じる。
[0003] Therefore, it is important to determine the patient's compliance, that is, how seriously the patient is taking it as instructed after the medication. Unpalatable preparations can also cause patients to fail to take them, and their improvement leads to increased compliance. Famotidine, cimetidine, ranitidine hydrochloride, nizatidine, H 2 blockers such as hydrochloric acid roxatidine acetate are capsules are formulated as tablets and powders. Although it is extremely insoluble in water, it has a large surface area, such as powders, granules, and chewable tablets, and in dosage forms that stay in the oral cavity for a while, bitterness causes a feeling of resistance when taken.

【0004】従来,散剤及び顆粒剤の添加剤としては,
造粒作業性,安定性並びに経済性などの点から,乳糖,
澱粉及び少量の甘味剤が使用されているが,H2ブロッ
カーの苦味を消すことはできない。また,乳糖,澱粉な
どは口腔内の少量の唾液で粘着性が出現することから,
服用感は決してよいとはいえない。通常,苦味物質の味
を改善するため,セルロース系,ポリアクリル酸系など
の腸溶性高分子,水不溶性高分子,胃溶性高分子AEA
などの他,脂肪酸及びその誘導体,油脂などを用い,苦
味物質あるいは苦味物質と乳糖などからなる芯物質に被
覆し苦味のマスキングを行う方法がとられる。特開平6
−219939号公報ではファモチジンの苦味隠蔽法と
して,ファモチジン,乳糖,PVPからなる粒に,セル
ロースアセテート及びまたはセルロースアセテートブチ
レート及びPVPからなる被覆剤を被覆してマスキング
が行なわれている。しかしながら,製造工程が多く複雑
であるうえ,アセトン,メタノールや塩化メチレンなど
有機溶媒を用いることによる作業環境の悪化が予想され
る。
[0004] Conventionally, additives for powders and granules include
From the viewpoints of granulation workability, stability and economy, lactose,
Starch and a small amount of sweetening agent is used, it can not be erased of H 2 blockers bitter. In addition, lactose, starch, etc. become sticky with a small amount of saliva in the oral cavity,
The feeling of taking is by no means good. Usually, enteric polymers such as cellulosic and polyacrylic acids, water-insoluble polymers, and gastric-soluble polymers AEA are used to improve the taste of bitter substances.
In addition to these methods, a method is used in which a bitter substance or a core substance comprising a bitter substance and lactose is coated with a fatty acid and its derivatives, oils and fats to mask bitterness. JP 6
In JP-A-219939, as a method of masking the bitterness of famotidine, masking is performed by coating a particle composed of famotidine, lactose, and PVP with a coating material composed of cellulose acetate and / or cellulose acetate butyrate and PVP. However, the production process is complicated and complicated, and the use of an organic solvent such as acetone, methanol or methylene chloride is expected to deteriorate the working environment.

【0005】[0005]

【発明が解決しようとする課題】本発明の目的は,工程
数の多い複雑な製造法を用いず,また,有機溶媒を使用
せずに,H2ブロッカーの苦味を改善した易服用性の固
形製剤及びその製造法を提供することにある。
SUMMARY OF THE INVENTION It is an object of the present invention, without using the process a large number of complicated manufacturing process, also without the use of organic solvents, easy taking of solid having improved of H 2 blockers bitter An object of the present invention is to provide a preparation and a method for producing the same.

【0006】[0006]

【課題を解決するための手段】本発明者らは,H2ブロ
ッカーの固形製剤について鋭意検討を重ねた結果,砂
糖,ブドウ糖等の様々な糖を添加しても苦味は改善され
なかったが,意外にも特定の糖アルコールを組み合わせ
ることで,H2ブロッカーにあらかじめ被覆マスキング
をする等の工程数の多い複雑な製造法を必要とせず,苦
味が改善され,かつ,易服用性の固形製剤が得られるこ
とを発見し,本発明を完成するに至った。本発明でいう
特定の糖アルコールとは,溶解熱が−60kJ/kg以
下好ましくは−100kJ/kg以下のものであり,こ
れらは苦味が改善されなかった砂糖,ブドウ糖と同程度
のあるいはそれ以下の甘味しかもたないにもかかわら
ず,H2ブロッカーの苦味改善効果を示すものである。
Means for Solving the Problems As a result of intensive studies on the solid preparation of H 2 blocker, the present inventors did not improve the bitterness by adding various sugars such as sugar and glucose. by combining a specific sugar alcohol surprisingly does not require a complicated production process with many number of steps, such that the pre-coated masking in H 2 blockers, bitterness is improved, and is easily taken of the solid preparation The inventors have found that the present invention can be obtained, and have completed the present invention. The specific sugar alcohols referred to in the present invention are those having a heat of dissolution of -60 kJ / kg or less, preferably -100 kJ / kg or less, which are the same as or less than sugar or glucose whose bitterness has not been improved. despite only has sweetness shows the bitterness-improving effect of the H 2 blocker.

【0007】溶解熱とは溶質を溶媒(水)に溶かすとき
に吸収又は発生する熱量で,吸収する場合を−,発生す
る場合を+であらわす。溶解熱が−60kJ/kg以下
とは60kJ/kgよりも吸収熱量が大きいことをい
う。本発明で用いられる糖アルコールとしては溶解熱が
−60KJ/kg以下のものであれば特に制限はなく,
−100KJ/kg以下であればより好ましい,例とし
ては,キシリトール,ソルビトール,マンニトール,エ
リスリトールなどが挙げられる。糖アルコールの溶解熱
が−60KJ/kg以下でない場合には,清涼感よりも
糖アルコールの甘味が重たく感じられ,H2ブロッカー
の苦味と相まって複雑な味となり,良好な服用感を得る
ことができない。例えば溶解熱が−60kJ/kg以下
でないマルチトール,ラクチトール等では苦味改善効果
は得られなかった。しかし、溶解熱が−60KJ/kg
以下好ましくは−100KJ/kg以下の糖アルコール
を用いることにより,苦味が改善され,清涼感があり,
口中ですみやかに溶解,崩解しうる易服用性のH2ブロ
ッカー固形製剤が提供し得た。これらの糖アルコールは
水に極めてとけ易く,甘味があるがインスリン作用を要
することなく細胞内に取り込まれるので血糖値を上昇さ
せることはない。本発明における「H2ブロッカー」と
は,例えばファモチジン,シメチジン,塩酸ラニチジ
ン,ニザチジン,塩酸ロキサチジンアセタート等があげ
られる。このうち特に好ましいものとしてはファモチジ
ンがあげられる。
[0007] The heat of dissolution is the amount of heat absorbed or generated when a solute is dissolved in a solvent (water), and is represented by-when absorbed and + when generated. The heat of dissolution of -60 kJ / kg or less means that the heat of absorption is greater than 60 kJ / kg. The sugar alcohol used in the present invention is not particularly limited as long as the heat of dissolution is −60 KJ / kg or less.
It is more preferable that the concentration is −100 KJ / kg or less. Examples thereof include xylitol, sorbitol, mannitol, erythritol and the like. When heat of dissolution of the sugar alcohol is not less -60KJ / kg, rather than cooling sensation is felt sweetness of sugar alcohols heavy, it is coupled with complicated flavor with H 2 blockers bitterness, it is impossible to obtain good ingestion feeling . For example, maltitol, lactitol and the like having a heat of dissolution of not more than -60 kJ / kg could not obtain a bitter taste improving effect. However, the heat of dissolution is -60 KJ / kg
By using a sugar alcohol of preferably -100 KJ / kg or less, the bitterness is improved, and there is a refreshing feeling.
Rapidly dissolved in the mouth, easy taking of H 2 blockers solid preparation which can disintegrate is obtained provided. These sugar alcohols are very easy to dissolve in water and have a sweet taste, but they are taken up into cells without the need for insulin action, so they do not raise blood sugar levels. The “H 2 blocker” in the present invention includes, for example, famotidine, cimetidine, ranitidine hydrochloride, nizatidine, roxatidine hydrochloride acetate and the like. Among them, famotidine is particularly preferred.

【0008】又,本発明における「固形製剤」には,散
剤,顆粒剤,咀嚼可能な錠剤等が含まれる。好ましくは
散剤,顆粒剤であり,最も好ましくは散剤である。そし
て本発明でいう散剤は細粒剤をも含むものである。本発
明で用いられる「易服用性」とは,清涼感があり,口中
ですみやかに溶解,崩解し,服用する際にざらつき感等
を伴わず,口当たりの良い服用し易い形態を提供しうる
ものである。
[0008] The "solid preparation" in the present invention includes powders, granules, chewable tablets and the like. Preferred are powders and granules, and most preferred are powders. The powder according to the present invention also includes fine granules. "Easy-to-take" as used in the present invention means that it has a refreshing sensation, dissolves and disintegrates quickly in the mouth, does not have a feeling of roughness when taken, and can provide a palatable, easy-to-take form. Things.

【0009】本発明において,溶解熱が−60KJ/k
g以下好ましくは−100KJ/kg以下の糖アルコー
ルはH2ブロッカー1部に対し,25部以上,好ましく
は40部以上であり,かつ,製剤全重量に対し,50%
〜99.9%,好ましくは80〜99.9%用いるのが
よい。これを外れると清涼感が薄れ,口中ですみやかに
溶解,崩解し得なくなり,良好な服用感が得られない。
また,本発明で用いるこれらの糖アルコールは,単独で
用いるのみでなく,2種以上を組み合わせることもでき
る。特に咀嚼可能な錠剤の様に適度な成形性を必要とす
る剤型には良好な成形性を有するソルビトールの添加が
望ましい。
In the present invention, the heat of solution is -60 KJ / k.
g or less preferably the following sugar alcohol -100KJ / kg whereas H 2 blockers 1 part, 25 parts or more, preferably not less than 40 parts, and, relative to total weight of the preparation, 50%
9999.9%, preferably 80-99.9%. If it is removed, the refreshing sensation will be weakened, it will not dissolve or disintegrate quickly in the mouth, and a good feeling of taking it will not be obtained.
These sugar alcohols used in the present invention can be used alone or in combination of two or more. In particular, it is desirable to add sorbitol having a good formability to a dosage form requiring an appropriate formability such as a chewable tablet.

【0010】更に,本発明において,1−メントールを
添加することで,溶解熱が−60KJ/kg以下好まし
くは−100KJ/kg以下の糖アルコールによるH2
ブロッカーの苦味改善効果を更に向上することができ
る。1−メントールの添加量としては通常1%以下好ま
しくは0.1%以下である。本発明で製したH2ブロッ
カーと溶解熱が−60KJ/kg以下好ましくは−10
0KJ/kg以下の糖アルコールまたは,H2ブロッカ
ーと溶解熱が−60KJ/kg以下好ましくは−100
KJ/kg以下の糖アルコール及び1−メントールから
なる組成物は,通常製剤化において用いられる賦形剤,
安定化剤,結合剤,滑沢剤,流動化剤,香料,甘味剤,
色素などを添加し,常法により,散剤,顆粒剤あるいは
錠剤好ましくは咀嚼可能な錠剤とすることができる。本
発明のH2ブロッカー固形製剤は,工程数の多い複雑な
製造法を要せず,しかも有害な有機溶媒を使わず,通常
行なわれている製造法を用い,少ない工程で製造するこ
とができる。
Further, in the present invention, by adding 1-menthol, H 2 by sugar alcohol having a heat of dissolution of -60 KJ / kg or less, preferably -100 KJ / kg or less is added.
The effect of improving the bitterness of the blocker can be further improved. The amount of 1-menthol added is usually 1% or less, preferably 0.1% or less. H 2 blockers and dissolution heat of manufacturing in the present invention is -60KJ / kg or less, preferably -10
0 KJ / kg or less of sugar alcohol or H 2 blocker and heat of dissolution is −60 KJ / kg or less, preferably −100
Compositions consisting of sugar alcohols of up to KJ / kg and 1-menthol can be used as excipients normally used in formulation,
Stabilizers, binders, lubricants, fluidizers, flavors, sweeteners,
By adding a pigment or the like, powders, granules or tablets, preferably chewable tablets, can be prepared by a conventional method. H 2 blockers solid preparation of the present invention, without requiring more complex manufacturing process of the number of steps, moreover without using harmful organic solvents, usually conducted are using the production method, can be produced in fewer steps .

【0011】(製造法)造粒方法として,通常の製造方
法である流動層造粒法,攪拌造粒法,高速攪拌造粒法,
転動流動造粒法などを用いて製造することができる。好
ましくは流動層造粒法,転動流動造粒法であり,中でも
流動層造粒法が最も適している。本発明で用いられる溶
解熱が−60KJ/kg以下好ましくは−100KJ/
kg以下の糖アルコールは,水に極めてとけ易いことか
ら,造粒中に水分過多による好ましくない粗粒子や塊が
できやすい。流動層造粒法は水分制御が簡単なため造粒
物の粒径制御が行ないやすく本発明の製造に最適であ
る。流動層造粒法を用いた製造方法を詳細に説明する
が,これらは本発明を限定するものではない。
(Production method) As the granulation method, fluidized bed granulation method, stirring granulation method, high-speed stirring granulation method, which is a usual production method,
It can be manufactured using a tumbling fluidized-granulation method or the like. The fluidized bed granulation method and the tumbling fluidized granulation method are preferred, and the fluidized bed granulation method is most suitable. The heat of dissolution used in the present invention is -60 KJ / kg or less, preferably -100 KJ / kg.
Since sugar alcohols of less than kg are extremely soluble in water, undesired coarse particles and agglomerates due to excessive moisture are likely to be formed during granulation. The fluidized-bed granulation method is easy to control the particle size of the granulated material because the moisture control is simple, and is most suitable for the production of the present invention. Production methods using fluidized bed granulation will be described in detail, but these do not limit the present invention.

【0012】1種あるいは2種以上の溶解熱が−60K
J/kg以下好ましくは−100KJ/kg以下の糖ア
ルコールと粉砕したH2ブロッカーを常法により,HP
C,PVP等の結合剤水溶液を用いて流動層造粒機で造
粒し,所望の粒径に調製した後,粉砕した1−メントー
ル及び軽質無水ケイ酸等の流動化剤を混合機で配合し,
散剤あるいは顆粒剤とすればよい。また,得られた造粒
物にステアリン酸マグネシウム,タルク等の滑沢剤を必
要量添加し,混合機で混合した後,常法により打錠機で
打錠し,咀嚼可能な錠剤とすることもできる。この際,
溶解熱が−60KJ/kg以下好ましくは−100KJ
/kg以下の糖アルコールが大きな粒径の結晶であると
きは,造粒の前に少量の流動化剤とともに予め粉砕処理
をすることが望ましい。また,H2ブロッカーが低含量
の場合,製剤中の均一な含量を得るため,結合剤水溶液
中に分散した後,溶解熱が−60KJ/kg以下好まし
くは−100KJ/kg以下の糖アルコールに噴霧しな
がら造粒することが望ましい。
One or more heats of dissolution are -60K
J / kg or less, preferably -100 KJ / kg or less, and crushed H 2 blocker were mixed with HP
After granulating with a fluidized bed granulator using an aqueous solution of a binder such as C or PVP and adjusting the particle size to a desired value, pulverized 1-menthol and a fluidizing agent such as light anhydrous silicic acid are blended with a mixer. And
Powders or granules may be used. Add the necessary amount of lubricant such as magnesium stearate, talc, etc. to the obtained granules, mix with a mixer, and tablet with a tableting machine by a conventional method to make chewable tablets. Can also. On this occasion,
Heat of dissolution is -60 KJ / kg or less, preferably -100 KJ
When the sugar alcohol of less than / kg is a crystal having a large particle size, it is desirable to carry out a pulverizing treatment with a small amount of a fluidizing agent before granulation. Spray Also, if H 2 blockers low content, in order to obtain a uniform content in the formulation, was dispersed in a binder solution, heat of dissolution is less preferred -60KJ / kg on the following sugar alcohol -100KJ / kg It is desirable to granulate while performing.

【0013】[0013]

【発明の効果】本発明によれば,砂糖と同程度あるいは
それ以下の甘味度を有する−60KJ/kg好ましくは
−100KJ/kgの糖アルコールにより、H2ブロッ
カーの苦味が改善された固形製剤が得られる。これらは
口中ですみやかに溶解,崩解し,服用する際にざらつき
感等を伴わず,口当たりのよい清涼感を伴った服用しや
すい製剤である。さらに、服用時に多量の水の摂取を必
要とせず,よりよい服用形態を提供し得るものである。
また,工程数の多い複雑な製造法を必要とせず,有機溶
媒による環境悪化もなく,一般の製造工程で製造される
ので,経済的で工業生産性の高いものである。
According to the present invention, a solid preparation in which the bitterness of an H 2 blocker is improved by a sugar alcohol having a sweetness similar to or less than that of sugar, ie, -60 KJ / kg, preferably -100 KJ / kg, is provided. can get. These preparations dissolve and disintegrate promptly in the mouth, and are easy to take with a pleasant refreshing sensation without a feeling of roughness when taken. Further, the present invention can provide a better dosage form without requiring a large amount of water to be taken.
In addition, since it does not require a complicated manufacturing method having many steps, does not deteriorate the environment due to an organic solvent, and is manufactured in a general manufacturing process, it is economical and has high industrial productivity.

【0014】[0014]

【実施例】以下,本発明のH2ブロッカー含有固形製剤
及び製造法を実施例に基づいて更に詳細に説明するが,
本発明はこれらの実施例に限定されるものではない。
EXAMPLES Hereinafter, described in more detail by of H 2 blockers containing solid preparation and a production method of the present invention in the Examples,
The present invention is not limited to these examples.

【0015】実施例1 キシリトール粉末667.8部及び軽質無水ケイ酸3.
5部を粗混合した後,流動層造粒機FLO−1にとり,
7.5%HPC水溶液140部に1.0mmスクリーン
付き微粉砕機で粉砕したファモチジン14部を分散した
液を噴霧し造粒した。得られた造粒物を30号篩いで篩
過し,軽質無水ケイ酸3.5部とともにV型混合機で1
0分間混合し,2%ファモチジン散剤を得た。
Example 1 667.8 parts of xylitol powder and light anhydrous silicic acid
After roughly mixing 5 parts, the mixture is taken into a fluidized bed granulator FLO-1.
A liquid in which 14 parts of famotidine pulverized with a 1.0-mm screen pulverizer was dispersed and sprayed into 140 parts of a 7.5% HPC aqueous solution was granulated. The obtained granules were sieved with a No. 30 sieve, and mixed with 3.5 parts of light anhydrous silicic acid in a V-type mixer.
After mixing for 0 minutes, a 2% famotidine powder was obtained.

【0016】実施例2 キシリトール粉末に替え,ソルビトール粉末667.8
部を用いた他は実施例1と同様にして2%ファモチジン
散剤を得た。
Example 2 Instead of xylitol powder, sorbitol powder 667.8
A 2% famotidine powder was obtained in the same manner as in Example 1 except that the parts were used.

【0017】実施例3 実施例1で得られた散剤299.7部に乳鉢粉砕した1
−メントール0.3部を加え,V型混合機で10分間混
合し,2%ファモチジン散剤を得た。
Example 3 299.7 parts of the powder obtained in Example 1 was ground with a mortar.
-0.3 part of menthol was added and mixed with a V-type mixer for 10 minutes to obtain a 2% famotidine powder.

【0018】実施例4 ソルビトール粉末457.3部,エリスリトール粉末2
00部及び軽質無水ケイ酸3.5部を粗混合した後,流
動層造粒機FLO−1にとり,10%HPC水溶液21
0部に1.0mmスクリーン付き微粉砕機で粉砕したフ
ァモチジン14部を分散した液を噴霧し造粒した。得ら
れた造粒物を12号篩いで篩過し,1−メントール0.
7部,軽質無水ケイ酸3.5部とともにV型混合機で1
0分間混合し,2%ファモチジン顆粒を得た。
Example 4 457.3 parts of sorbitol powder, erythritol powder 2
After roughly mixing 00 parts and 3.5 parts of light anhydrous silicic acid, the mixture was placed in a fluidized bed granulator FLO-1, and a 10% HPC aqueous solution 21 was added.
A liquid in which 14 parts of famotidine pulverized by a pulverizer with a 1.0 mm screen was dispersed in 0 part was sprayed and granulated. The obtained granules were sieved with a No. 12 sieve to give 1-menthol 0.1.
7 parts, 3.5 parts of light anhydrous silicic acid with V-type mixer 1
Mixing was performed for 0 minutes to obtain 2% famotidine granules.

【0019】実施例5 キシリトール粉末に替え,マンニトール粉末667.8
部を用いた他は実施例1と同様にして2%ファモチジン
散剤を得た。
Example 5 Mannitol powder 667.8 was used instead of xylitol powder.
A 2% famotidine powder was obtained in the same manner as in Example 1 except that the parts were used.

【0020】実施例6 実施例5で得られた散剤299.7部に乳鉢粉砕したl
−メントール0.3部を加え,V型混合機で10分間混
合し,2%ファモチジン散剤を得た。
Example 6 299.7 parts of the powder obtained in Example 5 was crushed with a mortar.
-0.3 part of menthol was added and mixed with a V-type mixer for 10 minutes to obtain a 2% famotidine powder.

【0021】実施例7 キシリトール粉末に替え,エリスリトール粉末667.
8部を用いた他は実施例1と同様にして2%ファモチジ
ン散剤を得た。
Example 7 Erythritol powder was used instead of xylitol powder.
A 2% famotidine powder was obtained in the same manner as in Example 1 except that 8 parts were used.

【0022】実施例8 実施例7で得られた散剤299.7部に乳鉢粉砕したl
−メントール0.3部を加え,V型混合機で10分間混
合し,2%ファモチジン散剤を得た。
Example 8 299.7 parts of the powder obtained in Example 7 was crushed with a mortar.
-0.3 part of menthol was added and mixed with a V-type mixer for 10 minutes to obtain a 2% famotidine powder.

【0023】実施例9 軽質無水ケイ酸1.0部にレモンフレーバー0.5部を
加え乳鉢中でよく混合した後,実施例2で得られた散剤
499.5部とともにV型混合機で10分間混合し,更
にステアリン酸マグネシウム10部を加え10分間混合
した後,単発型打錠機により1錠1022mg,直径1
5.0mm,厚さ5.5mmの錠剤に打錠し,1錠中フ
ァモチジン20mgを含有する咀嚼可能な錠剤を得た。
Example 9 0.5 part of lemon flavor was added to 1.0 part of light anhydrous silicic acid, mixed well in a mortar, and mixed with 499.5 parts of the powder obtained in Example 2 in a V-type mixer. After mixing for 10 minutes, 10 parts of magnesium stearate was further added and mixed for 10 minutes.
Tablets having a thickness of 5.0 mm and a thickness of 5.5 mm were tabletted to obtain chewable tablets containing 20 mg of famotidine in each tablet.

【0024】試験例1 実施例1〜4及び下記の比較例で得られたファモチジン
含有内服固形製剤につき,10名のパネラーの口中に2
0秒間含ませ,官能試験を行った。それぞれの苦味及び
清涼感,口当たり等の服用感につき,表1及び表2に示
す。 (比較例)1.0mmスクリーン付き微粉砕機で粉砕し
たファモチジン20部,乳糖845部,トウモロコシ澱
粉100部を流動層造粒機FLO−1にとり,10%H
PC水溶液300部を結合剤として造粒した後,30号
篩いで篩過し,軽質無水ケイ酸5部とともにV型混合機
で10分間混合し,2%ファモチジン散剤を得た。 <苦 味> 苦味を感じない :0 苦味を殆ど感じない :1 苦味をわずかに感じる:2 苦味を感じる :3
Test Example 1 The oral preparation of famotidine-containing solid preparation obtained in Examples 1 to 4 and the following Comparative Example was placed in the mouth of 10 panelists.
The sensory test was performed by allowing the sample to be included for 0 second. Tables 1 and 2 show the bitterness, the refreshing sensation, and the feeling of taking such as mouthfeel. (Comparative Example) 20 parts of famotidine, 845 parts of lactose and 100 parts of corn starch pulverized by a pulverizer with a 1.0 mm screen were placed in a fluidized bed granulator FLO-1 and 10% H was added.
After granulating 300 parts of an aqueous PC solution as a binder, the mixture was sieved with a No. 30 sieve and mixed with 5 parts of light anhydrous silicic acid for 10 minutes in a V-type mixer to obtain a 2% famotidine powder. <Bitterness> Bitterness is not felt: 0 Bitterness is hardly felt: 1 Bitterness is slightly felt: 2 Bitterness is felt: 3

【0025】[0025]

【表1】 表1の結果から明らかなように,糖アルコール以外の糖
(乳糖)を用いた比較例に比べ,同含量%のH2ブロッ
カー(ファモチジン)を含む実施例1〜4の製剤は,い
ずれも苦味を改善した。 <服用感> 服用感良好 :0 どちらでもない:1 服用感悪い :2
[Table 1] As is evident from the results in Table 1, all of the preparations of Examples 1 to 4 containing the same content of H 2 blocker (famotidine) in the same content as those of the comparative examples using sugar (lactose) other than sugar alcohol were bitter. Was improved. <Taking feeling> Good taking feeling: 0 Neither: 1 Bad feeling of taking: 2

【0026】[0026]

【表2】 表2の結果から明らかなように、実施例1〜4では、清
涼感があり、口中ですみやかに溶解、崩壊し服用される
際にざらつき感等を伴わず、口当たりが良好であるとの
結果を得た。一方、乳糖を用いた比較例では、清涼感は
伴わず、ざらつき、べとつき感を有し、良好な服用感は
得られなかった。
[Table 2] As is clear from the results in Table 2, in Examples 1 to 4, there was a refreshing sensation, the dissolution was promptly in the mouth , the disintegration was not accompanied by a feeling of roughness when taken, and the result that the mouthfeel was good. I got On the other hand, in the comparative example using lactose, there was no refreshing sensation, rough and sticky feeling, and good feeling of taking was not obtained.

【0027】試験例2 次の組成物98部それぞれにファモチジン2部及び1−
メントール0.1部を加え粉砕処理して製した散剤の官
能試験を5名のパネラーで行なった。それぞれの結果を
表3に示す。 苦味を感じない :0 苦味を殆ど感じない :1 苦味をわずかに感じる:2 苦味を感じる :3
Test Example 2 2 parts of famotidine and 1-
A powdery product produced by adding 0.1 part of menthol and pulverizing was subjected to a sensory test by five panelists. Table 3 shows the results. Bitter taste is not felt: 0 Bitter taste is hardly felt: 1 Bitter taste is slightly felt: 2 Bitterness is felt: 3

【0028】[0028]

【表3】 これらの結果からファモチジンの苦味改善効果には製剤
中50%以上の糖アルコールが有効であった。
[Table 3] From these results, 50% or more of the sugar alcohol in the preparation was effective in improving the bitter taste of famotidine.

【0029】試験例3 次の組成物98部それぞれにファモチジン2部あるいは
ファモチジン2部及び1−メントール0.1部を加え粉
砕処理して製した散剤の官能試験を5名のパネラーで行
なった。それぞれの結果を表4に示す。 苦味を感じない :0 苦味を殆ど感じない :1 苦味をわずかに感じる:2 苦味を感じる :3
Test Example 3 A powdery product prepared by pulverizing 2 parts of famotidine or 2 parts of famotidine and 0.1 part of 1-menthol to 98 parts of each of the following compositions was subjected to a sensory test by five panelists. Table 4 shows the results. Bitter taste is not felt: 0 Bitter taste is hardly felt: 1 Bitter taste is slightly felt: 2 Bitterness is felt: 3

【0030】[0030]

【表4】 結果から明らかなように,溶解熱が−60kJ/kg以
下の糖アルコールを用いた際には,苦味が改善された。
一方,溶解熱が−60kJ/kg以下でない糖アルコー
ル若しくはその他の糖類では,苦味改善効果はみられな
かった。また,溶解熱が−60kJ/kg以下の糖アル
コールを用い,さらにl−メントールを添加すること
で,苦味改善効果が向上した。
[Table 4] As is clear from the results, the bitterness was improved when a sugar alcohol having a heat of solution of −60 kJ / kg or less was used.
On the other hand, with sugar alcohols or other saccharides having a heat of dissolution of -60 kJ / kg or less, no bitterness improving effect was observed. In addition, by using a sugar alcohol having a heat of dissolution of −60 kJ / kg or less and further adding 1-menthol, the effect of improving bitterness was improved.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 47/10 A61K 9/14 L (56)参考文献 特開 昭62−32855(JP,A) 特表 平6−505498(JP,A) 別冊フードケミカル、平成2年12月20 日発行、第171−174頁及び第188−193頁──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code Agency reference number FI Technical display location A61K 47/10 A61K 9/14 L (56) References JP-A-62-32855 (JP, A) Tokuhyo Hei 6-505498 (JP, A) Separate volume Food Chemical, published December 20, 1990, pp. 171-174 and 188-193

Claims (7)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 溶解熱が−60kJ/kg以下の糖アル
コールを添加してなるH ブロッカー固形製剤であっ
て、H ブロッカー1部に対し糖アルコールが25部以
上であり、製剤中の糖アルコールの量が50〜99.9
%である苦味改善易服用性H ブロッカー固形製剤。
A sugar alcohol having a heat of dissolution of -60 kJ / kg or less.
There with H 2 blocker solid preparation obtained by adding a call
Te, sugar alcohols to H 2 blocker 1 part 25 parts or less
Above, wherein the amount of sugar alcohol in the formulation is 50-99.9
Bitterness improved easily taking ability H 2 blocker solid preparation is%.
【請求項2】 溶解熱が−60kJ/kg以下の糖アル
コールを添加してなるH ブロッカー固形製剤であっ
て、H ブロッカー1部に対し糖アルコールが40部以
上であり、製剤中の糖アルコールの量が80〜99.9
%である苦味改善易服用性H ブロッカー固形製剤。
2. A sugar alcohol having a heat of dissolution of -60 kJ / kg or less.
There with H 2 blocker solid preparation obtained by adding a call
Te, sugar alcohols to H 2 blocker 1 part 40 parts or less
Above, wherein the amount of sugar alcohol in the formulation is 80-99.9
Bitterness improved easily taking ability H 2 blocker solid preparation is%.
【請求項3】 固形製剤が散剤、顆粒剤、咀嚼可能な錠
剤である請求項1又は2記載の固形製剤。
3. A solid preparation powders, granules, solid preparation according to claim 1 or 2 wherein the chewable tablet.
【請求項4】 溶解熱が−100kJ/kg以下の糖ア
ルコールを添加してなる請求項1〜3記載の固形製剤。
4. The solid preparation according to claim 1, wherein a sugar alcohol having a heat of dissolution of -100 kJ / kg or less is added.
【請求項5】 l−メントールを添加してなる請求項1
記載の固形製剤。
5. The method according to claim 1, wherein l-menthol is added.
The solid preparation according to any one of claims 4 to 4 .
【請求項6】 糖アルコールがソルビトールである請求
項1〜記載の固形製剤。
6. A solid preparation according to claim 1-5, wherein the sugar alcohol is sorbitol.
【請求項7】 Hブロッカーがファモチジンである請
求項1〜記載の固形製剤。
7. A solid preparation according to claim 1 to 6, wherein H 2 blocker is famotidine.
JP6237963A 1994-09-30 1994-09-30 Easy to take bitterness improving H 改善 2H blocker solid preparation Expired - Lifetime JP2705787B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6237963A JP2705787B2 (en) 1994-09-30 1994-09-30 Easy to take bitterness improving H 改善 2H blocker solid preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6237963A JP2705787B2 (en) 1994-09-30 1994-09-30 Easy to take bitterness improving H 改善 2H blocker solid preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP14479497A Division JPH1053538A (en) 1997-06-03 1997-06-03 Easily administrable solid preparation of h2-blocker having reduced bitterness

Publications (2)

Publication Number Publication Date
JPH0899904A JPH0899904A (en) 1996-04-16
JP2705787B2 true JP2705787B2 (en) 1998-01-28

Family

ID=17023067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6237963A Expired - Lifetime JP2705787B2 (en) 1994-09-30 1994-09-30 Easy to take bitterness improving H 改善 2H blocker solid preparation

Country Status (1)

Country Link
JP (1) JP2705787B2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3800437B2 (en) * 1996-07-24 2006-07-26 大正製薬株式会社 Solution with reduced bitterness
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
WO1999016470A1 (en) * 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Oral preparation
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
CA2330485C (en) 1998-04-29 2008-07-08 Sumitomo Pharmaceuticals Co., Ltd. Oral formulation comprising biguanide and an organic acid
EP1161941A4 (en) * 1999-03-15 2002-08-28 Kaken Pharma Co Ltd Quickly disintegrating tablets and process for producing the same
KR100553019B1 (en) * 2003-06-19 2006-02-16 현대약품공업주식회사 Preparation method of chewable tablet of famotidine
JP5397026B2 (en) * 2009-06-05 2014-01-22 ゼリア新薬工業株式会社 Internal liquid
JP5412966B2 (en) * 2009-06-08 2014-02-12 ライオン株式会社 Granular preparation
JP2010174028A (en) * 2010-03-18 2010-08-12 Rohto Pharmaceut Co Ltd Intraorally soluble or chewing solid internal pharmaceutical composition containing bitter agent
JP2013028647A (en) * 2012-11-06 2013-02-07 Rohto Pharmaceutical Co Ltd Intraorally soluble or chewable solid internal pharmaceutical composition containing bitter drug
JP6867200B2 (en) * 2017-03-16 2021-04-28 株式会社ファンケル Proteoglycan-containing easily disintegrating tablets
CN113069550A (en) * 2021-04-13 2021-07-06 福州爱建生物科技有限公司 Taste masking agent formulation for reversible masking of bitter taste in the oral cavity by pre-administration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0578732B1 (en) * 1991-04-04 1996-06-19 The Procter & Gamble Company Chewable antacid compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
別冊フードケミカル、平成2年12月20日発行、第171−174頁及び第188−193頁

Also Published As

Publication number Publication date
JPH0899904A (en) 1996-04-16

Similar Documents

Publication Publication Date Title
DE69331839T2 (en) Fast-dissolving tablet and its manufacture
CA2032068C (en) Pharmaceutical lozenges
US6187336B1 (en) Process for producing a solid which is rapidly soluble in the oral cavity
JP4740740B2 (en) Drug-containing particles and solid preparation containing the particles
KR20090119993A (en) Oral disintegrating tablet
ES2713330T3 (en) Dry-coated tablet that disintegrates orally
EP2004146B1 (en) A tablet of paracetamol containing an encapsulated flavorant
KR20010030798A (en) Oral preparation
KR20130030306A (en) Pharmaceutical compositions
JP2705787B2 (en) Easy to take bitterness improving H 改善 2H blocker solid preparation
US5730997A (en) Tastemasked liquid pharmaceutical delivery system
JPH01313420A (en) Medical chewing table composition
HU207948B (en) Process for producing oral pimobendane compositions
WO2007086457A1 (en) Quickly disintegrating tablet produced by direct dry-tabletting
JP3418274B2 (en) Tablets with good oral feel
JP2000212094A (en) Pharmaceutical preparation for oral cavity
US4711777A (en) Pharmaceutical tablets
US20150141520A1 (en) Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
JP2007131561A (en) Oral solid preparation and method for producing the same
KR101302293B1 (en) Orally disintegrating powder comprising cilostazol and mannitol
DE19958228A1 (en) Medicinal product containing paroxetine methanesulfonate
JPH08310969A (en) Solid pharmaceutical composition and its preparation
WO2010119851A1 (en) Orally disintegrating tablet
JP2007534742A (en) Lozenge for sending out Dextromethorphan
KR101046789B1 (en) Amlodipine quick disintegrating tablet with improved stability and preparation method thereof

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071009

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081009

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091009

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101009

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111009

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111009

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121009

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121009

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121009

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131009

Year of fee payment: 16

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131009

Year of fee payment: 16

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131009

Year of fee payment: 16

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term